These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Focus on metformin - a major cardiovascular medication. 'Diabesity - the biggest epidemic in human history'. Straughan JL Cardiovasc J Afr; 2007; 18(5):331-3. PubMed ID: 17985034 [No Abstract] [Full Text] [Related]
3. Using insulin as a drug rather than as a replacement hormone during acute illness: a new paradigm. Pantaleo A; Zonszein J Heart Dis; 2003; 5(5):323-33. PubMed ID: 14503930 [TBL] [Abstract][Full Text] [Related]
5. [With diabetes into the mountains. The metabolism derails faster]. Roos M MMW Fortschr Med; 2005 Apr; 147(14):8. PubMed ID: 15887672 [No Abstract] [Full Text] [Related]
6. Risk modification for diabetic patients. Are other risk factors treated as diligently as glycemia? Shah BR; Mamdani M; Jaakkimainen L; Hux JE Can J Clin Pharmacol; 2004; 11(2):e239-44. PubMed ID: 15557673 [TBL] [Abstract][Full Text] [Related]
7. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Schindler C Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):7-26. PubMed ID: 19124392 [TBL] [Abstract][Full Text] [Related]
8. [Metabolism of adipose tissue in normal humans and in various metabolic disorders. II. The adipose tissue in metabolic diseases]. Sezille G; Jaillard J; Biserte G Ann Biol Clin (Paris); 1970; 28(3):209-15. PubMed ID: 5478256 [No Abstract] [Full Text] [Related]
15. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Lee M; Aronne LJ Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059 [TBL] [Abstract][Full Text] [Related]
16. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Chapman MJ; Sposito AC Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759 [TBL] [Abstract][Full Text] [Related]
18. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes. Darmon P; Curtillet C; Boullu S; Laugier A; Dutour A; Oliver C Diabetes Care; 1998 Sep; 21(9):1575. PubMed ID: 9727917 [No Abstract] [Full Text] [Related]
19. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. Haffner SM; Ruilope L; Dahlöf B; Abadie E; Kupfer S; Zannad F J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092 [TBL] [Abstract][Full Text] [Related]
20. The metabolic syndrome--from insulin resistance to obesity and diabetes. Gallagher EJ; LeRoith D; Karnieli E Endocrinol Metab Clin North Am; 2008 Sep; 37(3):559-79, vii. PubMed ID: 18775352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]